148 related articles for article (PubMed ID: 9371283)
1. Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321.
Anderson JE; Appelbaum FR
Curr Opin Hematol; 1994 May; 1(3):203-9. PubMed ID: 9371283
[TBL] [Abstract][Full Text] [Related]
2. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
[TBL] [Abstract][Full Text] [Related]
3. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
Vadhan-Raj S
Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
[TBL] [Abstract][Full Text] [Related]
4. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients.
Izquierdo MA; Degen D; Raymond E; Caron D; Ortiz V; Banks P; Von Hoff DD
Clin Cancer Res; 1996 Oct; 2(10):1713-6. PubMed ID: 9816121
[TBL] [Abstract][Full Text] [Related]
5. The effects of treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on human polymorphonuclear leukocyte function.
Buescher ES; McIlheran SM; Banks SM; Vadhan-Raj S
Exp Hematol; 1993 Oct; 21(11):1467-72. PubMed ID: 8405227
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
7. Hybrid cytokines as hematopoietic growth factors.
Williams DE; Park LS; Broxmeyer HE; Lu L
Int J Cell Cloning; 1991 Nov; 9(6):542-7. PubMed ID: 1770228
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-3 in hematology and oncology: current state of knowledge and future directions.
Mangi MH; Newland AC
Cytokines Cell Mol Ther; 1999 Jun; 5(2):87-95. PubMed ID: 10515681
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic growth factors: in vitro and in vivo studies in bone marrow transplantation.
Rizzoli V; Carlo-Stella C; Mangoni L; Bonati A
Int J Cell Cloning; 1990 Jan; 8 Suppl 1():270-7; discussion 277-8. PubMed ID: 2182739
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.
Schwartz GN; Kammula U; Warren MK; Park MK; Yan XY; Marincola FM; Gress RE
Stem Cells; 2000; 18(5):331-42. PubMed ID: 11007917
[TBL] [Abstract][Full Text] [Related]
13. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
14. Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction.
Lanza F; Rigolin GM; Castagnari B; Moretti S; Castoldi G
Haematologica; 1997; 82(2):239-45. PubMed ID: 9175331
[TBL] [Abstract][Full Text] [Related]
15. A GM-CSF/IL-3 fusion protein promotes neutrophil and platelet recovery in sublethally irradiated rhesus monkeys.
Williams DE; Dunn JT; Park LS; Frieden EA; Seiler FR; Farese AM; Macvittie TJ
Biotechnol Ther; 1993; 4(1-2):17-29. PubMed ID: 8374510
[TBL] [Abstract][Full Text] [Related]
16. A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplantation.
Barge AJ
Bone Marrow Transplant; 1993; 11 Suppl 2():1-11. PubMed ID: 8334433
[TBL] [Abstract][Full Text] [Related]
17. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF).
Akasheh M; Eastwood D; Vesole DH
Bone Marrow Transplant; 2003 Jan; 31(2):113-6. PubMed ID: 12621492
[TBL] [Abstract][Full Text] [Related]
18. In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells.
Aglietta M; De Felice L; Stacchini A; Petti MC; Bianchi AC; Aloe Spiriti MA; Sanavio F; Apra F; Piacibello W; Stern AC
Leukemia; 1991 Nov; 5(11):979-84. PubMed ID: 1961040
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
